The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.
The user wants to make a topical finasteride solution using wound cleanser with 70% IPA and add 40% propylene glycol due to headaches from minoxidil. They seek advice on using the wound cleanser and recommendations for pharmaceutical/cosmetic grade IPA in India.
The user reported significant hair improvement over 15 months using dutasteride, minoxidil (oral and topical), RU58841, ketoconazole, and microneedling. They are considering a hair transplant in 4-6 months.
The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.
The user is using a topical solution with finasteride, minoxidil, and tretinoin and is considering adding GHK-Cu to enhance hair growth and quality. Another user suggests diluting GHK-Cu and storing it in a smaller, refrigerated bottle.
The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.
Eucapil/fluridil is discussed as a potential treatment for hair loss, with questions about its effectiveness and why it isn't a primary treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
The conversation discusses the effectiveness and systemic absorption of Topilutamide/Fluridil/Eucapil and topical Dutasteride for hair loss. Users are sharing their experiences and seeking success stories with these treatments.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
Using a combination of topical finasteride, minoxidil, caffeine and dermaroller treatments to help with hair loss, while discussing the potential results and other options.
The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
Breezula, a potential hair loss treatment, is still in trials with no recent updates on its release, while its acne version, Winlevi, is available but expensive. Users discuss the high cost of hair loss treatments and alternatives like Minoxidil and topical Finasteride.
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
Treatments for hair loss, focusing on Fluridil/Topilutamide (Eucapil), Finasteride and RU58841 (Alfatradiol). The user reported that the Fluridil seemed to work well but had side effects of testicle ache, decreased mood and sex drive.
OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
The user is considering mixing 15mg of dutasteride with 60ml of castor oil for mesotherapy (micro-needling) to treat hair loss. They are asking if this method is viable.
The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.